This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy.
Accept
Decline
MENU
CLOSE
language
Powerful, accessible cell therapies for patients with cancer.

We develop innovative, highly effective cell therapies for cancer that are broadly accessible for patients.
FIND US
Acepodia USA
1600 Harbor Bay Parkway, Suite 140,
Alameda, CA 94502,
USA
Acepodia Taiwan
12F., No. 508, Sec. 7, Zhongxiao E. Rd.,
Nangang Dist., Taipei City 115011,
Taiwan (R.O.C.).
CONTACT US
Tel: +1 (415) 366 7822 Email: info@acepodiabio.com
FOLLOW US
Copyright © 2020 Acepodia Inc.
Privacy Policy Terms of use

Investors

CONTACT

If you have any questions or suggestions about investor services, please email   ir@acepodiabio.com
We sincerely thank you for your support to Acepodia.

Stock Transfer Agent
Taishin Securities Co., Ltd., Stock Transfer Agency Department

Tel: (02) 2504-8125 ext. 9

Address: B1, No. 96, Sec. 1, Jianguo N. Rd., Zhongshan Dist., Taipei City

Mailing Address:
P.O. Box 46-300, Taipei, Taiwan 104946

Website: 
https://www.tssco.com.tw/stocktransfer

 

Board Members

1. Board Members      (Term: February 6, 2026 – February 5, 2029)
Title Name Education & Experience
Chairman Yungscience Co., Ltd.
—Rep: Sonny Hsiao		 Education: B.S. in Chemistry, National Taiwan University;
                    Ph.D. in Chemistry & Molecular  and Cell Biology, UC Berkeley
Experience: Lecturer, UC Berkeley; Founder & CSO, Adheren, Inc.;
                     Founder/CEO, Acepodia Inc.
Director Carolyn Bertozzi Education: Ph.D. in Chemistry, UC Berkeley
Experience: T.Z. and Irmgard Chu Distinguished Professor of Chemistry, UC Berkeley;
                      Professor of Chemistry and Molecular & Cell Biology, UC Berkeley;
                      Professor of Molecular & Cellular Pharmacology, UCSF;
                      Senior Scientist,Lawrence Berkeley National Laboratory;
                      2022 Nobel Prize in Chemistry Laureate;
                      Anne T. and Robert M. Bass Professor of Chemistry, Stanford University;
                      Investigator, Howard Hughes Medical Institute; Board Member:
                      Alnylam Pharmaceuticals, OmniAb, Xaira Therapeutics, Eli Lilly;
                      Scientific  Advisory Board Member, Ono Pharmaceuticals
Director Digital Mobile Venture Ltd.
—Rep: Samuel Chen		 Education: B.S. in Chemistry, National Tsing Hua University
Experience: Director, Polaris Pharmaceuticals Group; Director, Polaris Biomedical;
                      Director, Linyang Biopharma;
                      Director, Sonix Technology;
                      Director, GlobalSat WorldCom;
                      Chairman, Jhumao Technology;
                      Chairman, Ampower Technology;
                      Chairman, Leison Technology
Director Digital Mobile Venture Ltd.
— Rep:KC Tsai		 Education: M.A. in Economics, Soochow University
Experience: Deputy General Manager, Capital Markets Division, Polaris Securities;
                      Chairman, Honguan Electronic Industries;
                      Chairman, Anfu Technology;
                      Chairman, Yiyou Management Consulting;
                      Independent Director, Sonix Technology;
                      Independent Director, Shuanglian Chemical;
                      Independent Director, Herchang Biotech;
                      Legal Entity Director Representative, Polaris Pharmaceuticals Group;
                      Director, Yangshen Biomedical;
                      Director, Tsing Microelectronics
Director Digital Mobile Venture Ltd.
— Rep: Brittany Wei		 Education: M.B.A. in Business Administration and M.S. in Information Management,
                    Boston University
Experience: Independent Director, GlobalSat WorldCom;
                      Director, Wisdom Photonics;
                      Compensation Committee Chair, Anfu Technology;
                      CEO, First Mastercard Business;
                      Legal Entity Director Representative, Polaris Pharmaceuticals Group
Independent Director Jo Shen Education: Ph.D. in Physical Chemistry, Lehigh University;
                   M.S. in Inorganic Chemistry, Iowa State University
Experience: Founding Partner, Vivo Capital;
                      Director, Handa Biopharma;
                      Director, Taiwan Liposome Company;
                      Director, Anhong Biomedical;
                      Director, Shenghua Biotech;
                      Legal Entity Director Representative, Dingsheng Biotech;
                      Independent Director, Shuntian Pharmaceutical Biotech;
                      Independent Director, Zhongen Biomedical Technology
Independent Director Angus Tsai Education: M.S. in Accounting, Chung Yuan Christian University
Experience: Deputy Director, Taiwan Securities OTC Center;
                      Associate Researcher, Taiwan Securities and Futures Market Development
                      Foundation;
                      CPA & IPO Advisory Accountant, Deloitte (Sustainability & IPO Division);
                      Legal Entity Director Representative, Tianyu Industrial;
                      Independent Director, Tiange International
Independent Director Kunming Rao Education: M.S. in Clinical Medicine, Chang Gung University
Experience: Cancer Molecular & Cell Biology Research, MD Anderson Cancer
                      Center,Texas;
                      Deputy Director of Internal Medicine, Italian Hospital for Cancer
                      Treatment; Supervisor, Taiwan Breast Oncology Society;
                      Standing Supervisor, Taiwan Hospice & Palliative Medicine Society;
                      Director, Taiwan Gastric Cancer Society;
                      Adjunct Professor, School of Medicine, I-Shou University
Independent Director Sung-Hsin Kuo Education: Ph.D. in Clinical Medicine, College of Medicine, National
                    Taiwan University
Experience: Attending Physician, Department of Oncology, NTU Hospital;
                      Professor, Graduate Institute of Oncology, NTU College of Medicine;
                      Chief, Division of Radiation Oncology, NTU Hospital
 
2. Board Diversity & Independence
(1) Board Diversity:
Directors are selected based on professional qualifications, experience, and diversity, without regard to gender, age, nationality, or cultural background.
The current board composition is as follows:
Board Diversity-new

Pursuant to Article 20 of the Company's "Corporate Governance Best Practice Principles" and Article 2 of the "Director Election Procedures," board members shall possess the knowledge, skills, and competencies required to perform their duties. The current board members have diverse professional backgrounds spanning biotechnology & healthcare, business management, finance & accounting, and industry experience, along with an international perspective, enabling them to effectively enhance the board's decision-making quality and oversight function.
The Company places great importance on board diversity and has established a diversity policy aligned with its business model and future development needs. This policy covers basic criteria such as gender, age, nationality, and cultural background, as well as professional competencies including industry expertise, finance, healthcare, and management.
The current board consists of nine directors (including four independent directors). The specific management objectives and achievement status of the diversity policy are as follows:
  • Gender Diversity: Three of the current directors are women, reflecting the Company's commitment to gender balance.
  • Director Serving as Executive: One director concurrently holds an executive management position, ensuring appropriate coordination between governance and operations.
  • Independent Director Ratio: Independent directors hold more than one-third of total board seats, meeting corporate governance standards and strengthening the board's oversight function.
  • Term Compliance: All current independent directors have served fewer than three consecutive terms, preserving their independence and objectivity in decision-making.
(2) Board Independence:
The Company's board of directors consists of nine directors with professional backgrounds and extensive experience, capable of providing expert perspectives from diverse disciplines, which greatly contributes to enhancing the Company's operational and management performance. The Company places great importance on board functionality and independence. No directors have spousal relationships or kinship within the second degree with any other director, in compliance with Articles 26-3(3) and 26-3(4) of the Securities and Exchange Act.